Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01369589 · ClinicalTrials.gov registry record · Phase 1
An Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal Wetness
A Phase 1 study of Sjogren's Syndrome and Xerostomia, sponsored by Parion Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT01369589 is a Phase 1 study of Sjogren's Syndrome and Xerostomia that has completed, run by Parion Sciences. The registered enrollment target is 24 participants, below the 287-participant average among 20 other Sjogren's Syndrome trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01369589, a Phase 1 study of Sjogren's Syndrome and Xerostomia, has completed, sponsored by Parion Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this clinical study is to determine the impact of P-552 oral rinse on salivary volume after administration of a single dose of P-552and versus vehicle rinse. Changes in oral mucosal wetness will be assessed via collection of salivary output and via measurement of oral wetness using the Periotron 8000 instrument.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG P-552
Study Locations (1)
Massachusetts
- Tufts University School of Dental Medicine - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2010-11 |
| Est. Completion | 2011-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01369589
The ClinicalTrials.gov registry entry for NCT01369589 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 287-participant average among 20 other Sjogren's Syndrome trials with a reported enrollment target (92% lower). The listed sponsor is Parion Sciences, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Sjogren's Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01369589 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01369589 about?
NCT01369589 is a clinical study titled "An Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal Wetness". The primary objective of this clinical study is to determine the impact of P-552 oral rinse on salivary volume after administration of a single dose of P-552and versus vehicle rinse. Changes in oral mucosal wetness will be assessed via collection of salivary output and via measurement of oral wetnes...
What is the current status of trial NCT01369589?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2010-11. Estimated completion is 2011-04.
What conditions does trial NCT01369589 study?
This clinical trial studies the following conditions: Sjogren's Syndrome, Xerostomia.
What interventions are being tested in trial NCT01369589?
The interventions under investigation include: Placebo (DRUG), P-552 (DRUG).
Who is sponsoring clinical trial NCT01369589?
This trial is sponsored by Parion Sciences, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01369589 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sjogren's Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease
RECRUITING · Phase 1
-
Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Syndrome
ACTIVE NOT RECRUITING · Phase 1
-
Anti-CD20 Antibody Therapy for Sjogren's Syndrome
COMPLETED · Phase 1
-
Omalizumab for Lupus
COMPLETED · Phase 1
-
Rheumatology Diet Study
RECRUITING
-
Creating Health Course Study for People With Rheumatological Conditions
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.